Vistin Pharma ASAFRA:VP4 -1.10%80 Net Margin % is 19.15% as of Mar. 2026, which is 96% above its 10-year median of 9.75. GuruFocus rates FRA:VP4 with a GF Score™ of 80/100 and a GF Value™ of €2.27 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 957 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 81.92% on this metric.
The historical rank and industry rank for Vistin Pharma ASA's Net Margin % or its related term are showing as below:
FRA:VP4'
s Net Margin % Range Over the Past 10 Years
Min: -38.3 Med: 9.75 Max: 39.84
Current: 16.59
FRA:VP4's Net Margin % is ranked better than 81.92% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs FRA:VP4: 16.59
Vistin Pharma ASA (FRA:VP4) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vistin Pharma ASA Net Margin % Related Terms
Vistin Pharma ASA Net Margin % Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VP4 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (FRA:VP4) has a Net Margin % of 19.15% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Vistin Pharma ASA and its competitors. This is 96% above median its historical median of 9.75. According to the industry distribution chart, Vistin Pharma ASA ranks #173 out of 957 companies in the Drug Manufacturers industry, placing it in the top 18.1%.
Is Vistin Pharma ASA's Net Margin % too high?
Vistin Pharma ASA's current Net Margin % of 19.15% is 96% above median its 10-year median of 9.75. The Drug Manufacturers industry median Net Margin % is 5.58. Vistin Pharma ASA's value of 19.15% is 243.2% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #173 out of 957 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #173 out of 957 companies for Net Margin %. This places Vistin Pharma ASA in the top 18% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.58. Vistin Pharma ASA's value of 19.15% is 243.2% above this benchmark. While the company's 10-year median is 9.75 vs. the industry median of 5.58, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Net Margin % of 19.15% is 243.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Net Margin % is 19.15%, which is 96% above median its own 10-year median of 9.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (FRA:VP4) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.27, compared to a current price of €1.79 — trading 21.1% below its estimated fair value. The current Net Margin % is 19.15%, which is 96% above median its 10-year median of 9.75 and 243.2% above the Drug Manufacturers industry median of 5.58. Vistin Pharma ASA's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vistin Pharma ASA (FRA:VP4), the current Net Margin % is 19.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (FRA:VP4) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of €1.79 is trading 21.1% below its estimated GF Value™ of €2.27.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for FRA:VP4:
Net Margin %: 19.15% (96% above median its 10-year median of 9.75)
GF Value™: €2.27 vs. price of €1.79 (21.1% below fair value)
Industry Position: 243.2% above the Drug Manufacturers median (#173 of 957)
No single metric tells the full story. See the FRA:VP4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score
Get the complete analysis for FRA:VP4
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VP4 has been successfully added to your 
